Aspect Partners
TLX icon

Aspect Partners’s Telix Pharmaceuticals TLX Stock Holding History

Aspect Partners’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.4K Hold
401
– – ﹤0.01% 416
2026
Q2 		$4.62K Buy
401
+21
+6% +$214 ﹤0.01% 430
2026
Q1 		$3.64K Buy
380
+28
+8% +$213 ﹤0.01% 407
2025
Q4 		$2.64K Buy
+352
New +$3.39K ﹤0.01% 475

Other funds holding TLX

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Aubrey Capital Management
Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return
WoodTrust Financial
WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Wilmington Savings Fund Society
Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

Aspect Partners's TLX Position: Q3 2026 in Review

Aspect Partners held its Telix Pharmaceuticals (TLX) position steady in Q3 2026 at 401 shares worth $4.4K. The position accounts for ﹤0.01% of the portfolio, ranked #416.

Aspect Partners first reported a position in TLX in Q4 2025 and has held it in 4 quarters since. The position peaked at $4.62K in Q2 2026. 12 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

  • Aspect Partners held 401 shares of Telix Pharmaceuticals worth $4.4K as of Q3 2026.
  • Aspect Partners left its Telix Pharmaceuticals share count unchanged in Q3 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #416 holding.
  • Aspect Partners first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Aspect Partners's Telix Pharmaceuticals position peaked at $4.62K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.